Importantly, compared to using only one regimen, combination of MNX1 depletion with anti‐CTLA‐4 antibody significantly inhibited the tumor growth, indicating that targeting MNX1 may be a potential method to enhance the therapeutic efficacy of CTLA‐4 inhibitor. This evidence concerns the gene MNX1 and neoplasm.